注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Athira Pharma Inc是一家臨床階段的生物製藥公司。該公司專注於開發小分子以恢復神經元健康和阻止神經退行性變。該公司的主要候選藥物fosgonimeton (ATH-1017)是一種皮下給藥、可穿透血腦屏障(BBB)的小分子HGF/MET正調節劑。該藥物主要目標適應症是阿爾茨海默病。ATH-1017是一種皮下給藥、穿透BBB的小分子肝細胞生長因子/間充質-上皮轉化因子 (HGF/MET) 激活劑,用於治療神經退行性疾病,最初的重點是阿爾茨海默病 (AD)。該公司還擁有非AD適應症的臨床前候選藥物,包括正在開髮用於解決外周適應症的ATH-1018,以及正在開髮用於解決神經精神適應症的ATH-1019/ATH-1020化合物。ATH技術旨在促進各種臨床應用的HGF/MET活性。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Kelly A. Romano | 60 | 2020 | Independent Chairwoman of the Board |
Mark J. Litton | 54 | 2019 | President, CEO & Director |
John M. Fluke | 79 | 2014 | Independent Director |
Joseph Eric Edelman | 66 | 2020 | Independent Director |
Marwan Noel Sabbagh | 56 | 2022 | Member of Scientific Advisory Board |
Grant E. Pickering | 54 | 2022 | Independent Director |
James A. Johnson | 65 | 2020 | Independent Director |
Barbara A. Kosacz | 64 | 2021 | Independent Director |
Anton P. Porsteinsson | - | 2022 | Member of Scientific Advisory Board |
Michael A. Panzara | 56 | 2022 | Independent Director |
John Olichney | - | 2022 | Member of Scientific Advisory Board |
Lon S. Schneider | - | 2022 | Member of Scientific Advisory Board |
Paul Winner | - | 2022 | Member of Scientific Advisory Board |
Pierre N. Tariot | - | 2022 | Member of Scientific Advisory Board |
Hans Moebius | 67 | 2019 | Chairman of Scientific Advisory Board |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核